PTC Therapeutics agrees to acquire Sangamo ST-920 Fabry assets
PTC Therapeutics agreed to acquire Sangamo assets primarily related to ST-920, an AAV gene therapy product candidate for Fabry disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.